1887

Abstract

Adenoviral vectors based on adenovirus type 35 (rAd35) have the advantage of low natural vector immunity and induce strong, insert-specific T- and B-cell responses, making them prime-candidate vaccine carriers. However, severe vector-genome instability of E1-deleted rAd35 vectors was observed, hampering universal use. The instability of E1-deleted rAd35 vector proved to be caused by low pIX expression induced by removal of the pIX promoter, which was located in the E1B region of B-group viruses. Reinsertion of a minimal pIX promoter resulted in stable vectors able to harbour large DNA inserts (>5 kb). In addition, it is shown that replacement of the E4-Orf6 region of Ad35 by the E4-Orf6 region of Ad5 resulted in successful propagation of an E1-deleted rAd35 vector on existing E1-complementing cell lines, such as PER.C6 cells. The ability to produce these carriers on PER.C6 contributes significantly to the scale of manufacturing of rAd35-based vaccines. Next, a stable rAd35 vaccine was generated carrying antigens Ag85A, Ag85B and TB10.4. The antigens were fused directly, resulting in expression of a single polyprotein. This vaccine induced dose-dependent CD4 and CD8 T-cell responses against multiple antigens in mice. It is concluded that the described improvements to the rAd35 vector contribute significantly to the further development of rAd35 carriers for mass-vaccination programmes for diseases such as tuberculosis, AIDS and malaria.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81956-0
2006-08-01
2019-08-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/8/2135.html?itemId=/content/journal/jgv/10.1099/vir.0.81956-0&mimeType=html&fmt=ahah

References

  1. Arribillaga, L., de Cerio, A. L. D., Sarobe, P. & 9 other authors ( 2002; ). Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 21, 202–210.[CrossRef]
    [Google Scholar]
  2. Babiss, L. E. & Vales, L. D. ( 1991; ). Promoter of the adenovirus polypeptide IX gene: similarity to E1B and inactivation by substitution of the simian virus 40 TATA element. J Virol 65, 598–605.
    [Google Scholar]
  3. Barouch, D. H. & Nabel, G. J. ( 2005; ). Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16, 149–156.[CrossRef]
    [Google Scholar]
  4. Barouch, D. H., McKay, P. F., Sumida, S. M. & 8 other authors ( 2003; ). Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77, 8729–8735.[CrossRef]
    [Google Scholar]
  5. Barouch, D. H., Pau, M. G., Custers, J. H. H. V. & 15 other authors ( 2004; ). Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172, 6290–6297.[CrossRef]
    [Google Scholar]
  6. Bett, A. J., Prevec, L. & Graham, F. L. ( 1993; ). Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67, 5911–5921.
    [Google Scholar]
  7. Caravokyri, C. & Leppard, K. N. ( 1995; ). Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. J Virol 69, 6627–6633.
    [Google Scholar]
  8. Casimiro, D. R., Chen, L., Fu, T.-M. & 36 other authors ( 2003; ). Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77, 6305–6313.[CrossRef]
    [Google Scholar]
  9. Cohen, C. J., Xiang, Z. Q., Gao, G.-P., Ertl, H. C. J., Wilson, J. M. & Bergelson, J. M. ( 2002; ). Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 83, 151–155.
    [Google Scholar]
  10. Colby, W. W. & Shenk, T. ( 1981; ). Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX. J Virol 39, 977–980.
    [Google Scholar]
  11. Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A., Van Ormondt, H., Hoeben, R. C. & Van Der Eb, A. J. ( 1996; ). Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7, 215–222.[CrossRef]
    [Google Scholar]
  12. Fallaux, F. J., Bout, A., van der Velde, I. & 9 other authors ( 1998; ). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9, 1909–1917.[CrossRef]
    [Google Scholar]
  13. Ghosh-Choudhury, G., Haj-Ahmad, Y. & Graham, F. L. ( 1987; ). Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J 6, 1733–1739.
    [Google Scholar]
  14. Holterman, L., Vogels, R., van der Vlugt, R. & 15 other authors ( 2004; ). Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78, 13207–13215.[CrossRef]
    [Google Scholar]
  15. Jaiswal, S., Khanna, N. & Swaminathan, S. ( 2003; ). Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol 77, 12907–12913.[CrossRef]
    [Google Scholar]
  16. Jones, D., Kroos, N., Anema, R. & 12 other authors ( 2003; ). High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol Prog 19, 163–168.[CrossRef]
    [Google Scholar]
  17. Kostense, S., Koudstaal, W., Sprangers, M. & 8 other authors ( 2004; ). Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213–1216.[CrossRef]
    [Google Scholar]
  18. Lemckert, A. A. C., Sumida, S. M., Holterman, L. & 10 other authors ( 2005; ). Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J Virol 79, 9694–9701.[CrossRef]
    [Google Scholar]
  19. Liu, R.-Y., Wu, L.-Z., Huang, B.-J. & 9 other authors ( 2005; ). Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res 112, 24–31.[CrossRef]
    [Google Scholar]
  20. Lutz, P., Rosa-Calatrava, M. & Kedinger, C. ( 1997; ). The product of the adenovirus intermediate gene IX is a transcriptional activator. J Virol 71, 5102–5109.
    [Google Scholar]
  21. Maizel, J. V., Jr, White, D. O. & Scharff, M. D. ( 1968; ). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115–125.[CrossRef]
    [Google Scholar]
  22. Ophorst, O. J. A. E., Radošević, K., Havenga, M. J. E., Pau, M. G., Holterman, L., Berkhout, B., Goudsmit, J. & Tsuji, M. ( 2006; ). Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 74, 313–320.[CrossRef]
    [Google Scholar]
  23. Phillpotts, R. J., O'Brien, L., Appleton, R. E., Carr, S. & Bennett, A. ( 2005; ). Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 23, 1615–1623.[CrossRef]
    [Google Scholar]
  24. Pinto, A. R., Fitzgerald, J. C., Giles-Davis, W., Gao, G. P., Wilson, J. M. & Ertl, H. C. J. ( 2003; ). Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171, 6774–6779.[CrossRef]
    [Google Scholar]
  25. Pinto, A. R., Fitzgerald, J. C., Gao, G. P., Wilson, J. M. & Ertl, H. C. J. ( 2004; ). Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine 22, 697–703.[CrossRef]
    [Google Scholar]
  26. Rosa-Calatrava, M., Grave, L., Puvion-Dutilleul, F., Chatton, B. & Kedinger, C. ( 2001; ). Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J Virol 75, 7131–7141.[CrossRef]
    [Google Scholar]
  27. Rosa-Calatrava, M., Puvion-Dutilleul, F., Lutz, P., Dreyer, D., de Thé, H., Chatton, B. & Kedinger, C. ( 2003; ). Adenovirus protein IX sequesters host-cell promyelocytic leukaemia protein and contributes to efficient viral proliferation. EMBO Rep 4, 969–975.[CrossRef]
    [Google Scholar]
  28. Rubenwolf, S., Schütt, H., Nevels, M., Wolf, H. & Dobner, T. ( 1997; ). Structural analysis of the adenovirus type 5 E1B 55-kilodalton–E4orf6 protein complex. J Virol 71, 1115–1123.
    [Google Scholar]
  29. Sargent, K. L., Meulenbroek, R. A. & Parks, R. J. ( 2004; ). Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J Virol 78, 5032–5037.[CrossRef]
    [Google Scholar]
  30. Seaman, M. S., Xu, L., Beaudry, K. & 11 other authors ( 2005; ). Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79, 2956–2963.[CrossRef]
    [Google Scholar]
  31. Shabram, P. W., Giroux, D. D., Goudreau, A. M. & 7 other authors ( 1997; ). Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8, 453–465.[CrossRef]
    [Google Scholar]
  32. Shanley, J. D. & Wu, C. A. ( 2003; ). Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. Vaccine 21, 2632–2642.[CrossRef]
    [Google Scholar]
  33. Shiver, J. W. & Emini, E. A. ( 2004; ). Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55, 355–372.[CrossRef]
    [Google Scholar]
  34. Shiver, J. W., Fu, T.-M., Chen, L. & 49 other authors ( 2002; ). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335.[CrossRef]
    [Google Scholar]
  35. Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Xu, L., Yang, Z.-Y., Roederer, M., Koup, R. A., Jarhling, P. B. & Nabel, G. J. ( 2003; ). Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681–684.[CrossRef]
    [Google Scholar]
  36. Sumida, S. M., Truitt, D. M., Lemckert, A. A. C. & 15 other authors ( 2005; ). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174, 7179–7185.[CrossRef]
    [Google Scholar]
  37. Tan, Y., Hackett, N. R., Boyer, J. L. & Crystal, R. G. ( 2003; ). Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther 14, 1673–1682.[CrossRef]
    [Google Scholar]
  38. Vogels, R., Zuijdgeest, D., van Rijnsoever, R. & 20 other authors ( 2003; ). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77, 8263–8271.[CrossRef]
    [Google Scholar]
  39. Weigel, S. & Dobbelstein, M. ( 2000; ). The nuclear export signal within the E4orf6 protein of adenovirus type 5 supports virus replication and cytoplasmic accumulation of viral mRNA. J Virol 74, 764–772.[CrossRef]
    [Google Scholar]
  40. Wu, L., Kong, W.-P. & Nabel, G. J. ( 2005; ). Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79, 8024–8031.[CrossRef]
    [Google Scholar]
  41. Xiang, Z., Gao, G., Reyes-Sandoval, A., Cohen, C. J., Li, Y., Bergelson, J. M., Wilson, J. M. & Ertl, H. C. J. ( 2002; ). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76, 2667–2675.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81956-0
Loading
/content/journal/jgv/10.1099/vir.0.81956-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error